Global Pharmacovigilance Market - 2026-2031
Global Pharmacovigilance Marketis is growing with a CAGR of 12.43% during the forecast period 2026-2035.
The Global Pharmacovigilance Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Pharmacovigilance Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Service Provider
Both primary and secondary data sources have been used in the global Global Pharmacovigilance Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Global Pharmacovigilance Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Pharmacovigilance Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Service Provider
- Contract Outsourcing*
- In-house
- Intensified ADR Reporting*
- Spontaneous Reporting
- Cohort Event Monitoring
- Targeted Spontaneous Reporting
- EHR Mining
- Preclinical*
- Phase I
- Phase II
- Phase III
- Phase IV
- Hospitals*
- Pharmaceutical Companies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Global Pharmacovigilance Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Service Provider
3.2. Market snippet By Type of Reporting
3.3. Market snippet By Clinical Trial Phase
3.4. Market Snippet By End Users
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing trend of outsourcing pharmacovigilance services
4.1.1.2. Growing Incidence Rates of Adverse Drug Reaction and Drug Toxicity
4.1.2. Restraints:
4.1.2.1. The lack of skilled healthcare professionals and the high risk for data security
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer Strategic Initiatives
6.6. Conclusion
7. BY SERVICE PROVIDER
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider Segment
7.1.2. Market Attractiveness Index, By Service Provider Segment
7.2. Contract Outsourcing*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. In-house
8. BY TYPE OF REPORTING
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
8.1.2. Market Attractiveness Index, By Type of Reporting
8.2. Intensified ADR Reporting*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Spontaneous Reporting
8.4. Cohort Event Monitoring
8.5. Targeted Spontaneous Reporting
8.6. EHR Mining
9. BY CLINICAL TRIAL PHASE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
9.1.2. Market Attractiveness Index, By Clinical Trial Phase Segment
9.2. Preclinical*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Phase I
9.4. Phase II
9.5. Phase III
9.6. Phase IV
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User Segment
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Pharmaceutical Companies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. COMPANY PROFILES
13.1. Accenture*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. ArisGlobal
13.3. BioClinica
13.4. Capgemini
13.5. Cognizant
13.6. FMD K&L Inc.
13.7. Foresight Group International AG
13.8. IBM Corporation
13.9. Wipro Limited
13.10. IQVIA (*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Therapeutic devices
14.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Service Provider
3.2. Market snippet By Type of Reporting
3.3. Market snippet By Clinical Trial Phase
3.4. Market Snippet By End Users
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing trend of outsourcing pharmacovigilance services
4.1.1.2. Growing Incidence Rates of Adverse Drug Reaction and Drug Toxicity
4.1.2. Restraints:
4.1.2.1. The lack of skilled healthcare professionals and the high risk for data security
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer Strategic Initiatives
6.6. Conclusion
7. BY SERVICE PROVIDER
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider Segment
7.1.2. Market Attractiveness Index, By Service Provider Segment
7.2. Contract Outsourcing*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. In-house
8. BY TYPE OF REPORTING
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
8.1.2. Market Attractiveness Index, By Type of Reporting
8.2. Intensified ADR Reporting*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Spontaneous Reporting
8.4. Cohort Event Monitoring
8.5. Targeted Spontaneous Reporting
8.6. EHR Mining
9. BY CLINICAL TRIAL PHASE
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
9.1.2. Market Attractiveness Index, By Clinical Trial Phase Segment
9.2. Preclinical*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Phase I
9.4. Phase II
9.5. Phase III
9.6. Phase IV
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User Segment
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Pharmaceutical Companies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. COMPANY PROFILES
13.1. Accenture*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. ArisGlobal
13.3. BioClinica
13.4. Capgemini
13.5. Cognizant
13.6. FMD K&L Inc.
13.7. Foresight Group International AG
13.8. IBM Corporation
13.9. Wipro Limited
13.10. IQVIA (*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Therapeutic devices
14.3. Contact Us
